Dare Bioscience (DARE) Competitors $2.10 +0.07 (+3.45%) Closing price 04:00 PM EasternExtended Trading$2.10 0.00 (-0.24%) As of 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DARE vs. BMEA, PLRX, EQ, IFRX, VTGN, TCRX, ONCY, HLVX, COYA, and SRZNShould you be buying Dare Bioscience stock or one of its competitors? The main competitors of Dare Bioscience include Biomea Fusion (BMEA), Pliant Therapeutics (PLRX), Equillium (EQ), InflaRx (IFRX), VistaGen Therapeutics (VTGN), TScan Therapeutics (TCRX), Oncolytics Biotech (ONCY), HilleVax (HLVX), Coya Therapeutics (COYA), and Surrozen (SRZN). These companies are all part of the "pharmaceutical products" industry. Dare Bioscience vs. Its Competitors Biomea Fusion Pliant Therapeutics Equillium InflaRx VistaGen Therapeutics TScan Therapeutics Oncolytics Biotech HilleVax Coya Therapeutics Surrozen Dare Bioscience (NASDAQ:DARE) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment. Do institutionals and insiders have more ownership in DARE or BMEA? 6.7% of Dare Bioscience shares are owned by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are owned by institutional investors. 4.8% of Dare Bioscience shares are owned by insiders. Comparatively, 18.4% of Biomea Fusion shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts recommend DARE or BMEA? Dare Bioscience presently has a consensus price target of $10.00, indicating a potential upside of 376.19%. Biomea Fusion has a consensus price target of $14.80, indicating a potential upside of 632.67%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts plainly believe Biomea Fusion is more favorable than Dare Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Biomea Fusion 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 3 Strong Buy rating(s) 3.17 Is DARE or BMEA more profitable? Dare Bioscience's return on equity of 0.00% beat Biomea Fusion's return on equity.Company Net Margins Return on Equity Return on Assets Dare BioscienceN/A N/A -103.70% Biomea Fusion N/A -243.95%-140.74% Which has more volatility and risk, DARE or BMEA? Dare Bioscience has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.13, meaning that its stock price is 113% less volatile than the S&P 500. Does the media prefer DARE or BMEA? In the previous week, Biomea Fusion had 3 more articles in the media than Dare Bioscience. MarketBeat recorded 5 mentions for Biomea Fusion and 2 mentions for Dare Bioscience. Dare Bioscience's average media sentiment score of 1.45 beat Biomea Fusion's score of 1.22 indicating that Dare Bioscience is being referred to more favorably in the media. Company Overall Sentiment Dare Bioscience Positive Biomea Fusion Positive Which has higher earnings and valuation, DARE or BMEA? Dare Bioscience has higher revenue and earnings than Biomea Fusion. Dare Bioscience is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDare Bioscience$10K2,830.80-$4.05M-$2.14-0.98Biomea FusionN/AN/A-$138.43M-$3.03-0.67 SummaryBiomea Fusion beats Dare Bioscience on 8 of the 15 factors compared between the two stocks. Get Dare Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DARE vs. The Competition Export to ExcelMetricDare BioscienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.36M$3.12B$5.73B$10.31BDividend YieldN/A2.36%5.90%4.63%P/E Ratio-0.988.1457.1222.76Price / Sales2,830.80446.35528.74123.58Price / CashN/A45.4037.1760.46Price / Book-3.049.6212.796.29Net Income-$4.05M-$53.28M$3.28B$270.51M7 Day Performance-2.78%0.31%0.22%2.15%1 Month Performance-4.55%4.58%4.61%6.35%1 Year Performance-35.98%9.24%68.33%25.48% Dare Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAREDare Bioscience2.7026 of 5 stars$2.10+3.4%$10.00+376.2%-38.7%$27.36M$10K-0.9830Positive NewsShort Interest ↓BMEABiomea Fusion3.5257 of 5 stars$1.81-5.7%$14.80+717.7%-75.0%$114.26MN/A-0.6050News CoveragePositive NewsPLRXPliant Therapeutics4.1053 of 5 stars$1.73-7.0%$8.19+373.3%-87.3%$114.18M$1.58M-0.5190Positive NewsEQEquillium0.8953 of 5 stars$1.88-1.6%$1.00-46.8%+96.6%$113.65M$41.10M-3.3640Short Interest ↓IFRXInflaRx3.0868 of 5 stars$1.58-4.2%$6.20+292.4%-14.0%$110.77M$180K-1.9760Short Interest ↓VTGNVistaGen Therapeutics1.0564 of 5 stars$3.48-2.0%N/A-1.2%$108.92M$490K-1.9640News CoverageShort Interest ↑Gap DownTCRXTScan Therapeutics3.2873 of 5 stars$1.88-1.6%$7.80+314.9%-70.6%$108.39M$2.82M-1.72100Positive NewsONCYOncolytics Biotech2.4147 of 5 stars$1.28+20.8%$5.00+290.6%+29.7%$106.38MN/A-4.7430News CoverageGap UpHigh Trading VolumeHLVXHilleVax1.4894 of 5 stars$2.09-0.5%$2.00-4.3%+14.8%$105.30MN/A-1.4620News CoveragePositive NewsShort Interest ↑COYACoya Therapeutics3.099 of 5 stars$6.37+1.6%$16.50+159.0%-11.3%$104.87M$423.45K-5.146News CoverageSRZNSurrozen2.9589 of 5 stars$11.36-6.9%$38.50+238.9%+35.8%$104.56M$10.65M-0.7980Positive News Related Companies and Tools Related Companies Biomea Fusion Alternatives Pliant Therapeutics Alternatives Equillium Alternatives InflaRx Alternatives VistaGen Therapeutics Alternatives TScan Therapeutics Alternatives Oncolytics Biotech Alternatives HilleVax Alternatives Coya Therapeutics Alternatives Surrozen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DARE) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dare Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dare Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
